Printer Friendly

IMMULOGIC ANNOUNCES START OF HUMAN CLINICAL TRIAL PROGRAM FOR CATVAX CAT ALLERGY THERAPY

 IMMULOGIC ANNOUNCES START OF HUMAN CLINICAL TRIAL PROGRAM
 FOR CATVAX CAT ALLERGY THERAPY
 CAMBRIDGE, Mass., April 9 /PRNewswire/ -- ImmuLogic Pharmaceutical Corporation (NASDAQ: IMUL) today announced that the company is beginning the human clinical trial program for its CATVAX(tm) cat allergy therapeutic. The company's CATVAX product is intended to reduce or eliminate allergic reactions to cats, an immune disorder afflicting over five million people in the United States alone. CATVAX is the first of ImmuLogic's ALLERVAX(tm) family of allergy therapeutics to enter clinical trials. ALLERVAX products currently under development include treatments for allergies to ragweed, dust mites, Japanese cedar and grasses.
 The initial trial, a Phase I study being conducted under an Investigational New Drug Applications (IND) submitted earlier this year to the U.S. Food and Drug Administration, is designed primarily to assess safety. This study will be conducted in patients who are allergic to cats but are otherwise healthy.
 "The biological activity of CATVAX takes advantage of a newly- recognized behavior of the immune system," commented Dr. Malcolm Gefter, ImmuLogic's chairman and founding scientist. "Specific immunity to molecules like allergens can be selectively turned off by the administration of biologically reactive components derived from the allergen itself. In our preclinical studies we have demonstrated that the active components in CATVAX inhibit the immune system response to the allergen. These components are derived from the protein from cats that has been shown to be responsible for cat allergy."
 Beyond validating the activity of CATVAX in humans, the clinical trial program has the potential to establish a new paradigm for treating other immune disorders, including other allergies and autoimmune diseases. "We believe that these trials, if successful, will give us information that will help us begin to make real inroads in treating disorders that are not well treated today," Gefter added.
 ImmuLogic is developing products to treat allergies and autoimmune diseases. The company's technical approach is based upon proprietary discoveries and an advanced understanding of the molecular events controlling the human immune system. ImmuLogic is developing the ALLERVAX family of allergy therapeutics under a joint commercialization agreement with Marion Merrell Dow Inc., and the company is collaborating with Merck & Co. to develop treatments for Type I diabetes and rheumatoid arthritis.
 -0- 4/9/92
 /CONTACT: Janet Bush of ImmuLogic Pharmaceutical, 617-494-0060/
 (IMUL) CO: ImmuLogic Pharmaceutical Corporation ST: Massachusetts IN: MTC SU:


EG -- NE004 -- 6591 04/09/92 08:51 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 9, 1992
Words:401
Previous Article:LIMITED, INC. SALES UP 3 PERCENT
Next Article:SIMPSON INDUSTRIES ANNOUNCES OFFERING


Related Articles
IMMULOGIC AND MARION MERRELL DOW SIGN COLLABORATION AGREEMENT TO COMMERCIALIZE IMMULOGIC'S ALLERVAX ALLERGY PRODUCTS
IMMULOGIC APPOINTS SENIOR DIRECTOR, REGULATORY AFFAIRS
IMMULOGIC REPORTS FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS
IMMULOGIC AND MARION MERRELL DOW SIGN FINAL ALLERVAX PRODUCT COMMERCIALIZATION AGREEMENT
IMMULOGIC STUDIES OPEN WAY TO NEW TREATMENTS FOR ALLERGIC DISEASES
IMMULOGIC REPORTS FIRST QUARTER RESULTS
IMMULOGIC REPORTS SECOND QUARTER RESULTS
IMMULOGIC REPORTS SECOND QUARTER RESULTS
ImmuLogic Files Investigational New Drug Application with the FDA for Multiple Sclerosis Therapeutic
ImmuLogic Reports Positive Results From 1996 ALLERVAX RAGWEED Product Trial

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters